Indianapolis Pharmaceutical Distributors: 8 Restructuring Moves When Your Collateral Needs a License

What a Blanket Lien Reaches Inside a Licensed Warehouse, and What It Does Not

A distribution company on the northwest side keeps most of its balance sheet in the racks, so a receivables desk underwriting an advance against that company is looking at an inventory line that dwarfs every other number on the statement. Nothing about that arithmetic is wrong on its own terms, and the inventory really is the largest asset the company owns. What the arithmetic leaves out is that prescription drug inventory is close to the only category of ordinary commercial collateral a secured creditor may be legally barred from receiving, from holding, and from reselling, because the right to move the product at all runs with a license the creditor does not hold and cannot borrow for an afternoon. The distance between what the security agreement describes and what the secured party may lawfully do with it is the most valuable fact in an Indianapolis pharmaceutical distribution file, and it is rarely priced by either side.

Everything below is built on the statutes that create that distance. They are the Drug Supply Chain Security Act at 21 U.S.C. §360eee through §360eee-4, the licensing command at 21 U.S.C. §353(e), and the Indiana wholesale drug distributor chapter at Ind. Code §25-26-14. Alongside them sit the Controlled Substances Act registration framework at 21 U.S.C. §823 with its transfer rules at 21 C.F.R. §1301.52, and Indiana’s enactment of Article 9 at Ind. Code §26-1-9.1. The eight items run in the order a distributor should work them, starting with the ones that change what you say on the next phone call and ending with the ones that decide whether this business survives whole or gets broken up and sold for the parts that are legal to sell.

A page that hands you only the favorable half of this will get you hurt, so the concession comes before the argument. Every rule that makes your inventory awkward for a funder to liquidate does precisely nothing to protect your accounts receivable, and the accounts are where a creditor with competent counsel goes on day one. An owner who spends a negotiation lecturing a collections manager about transaction statements, while a notification under Ind. Code §26-1-9.1-406(a) is already in front of the three hospital systems and the GPO that owe the company money, has converted a genuinely strong argument into a genuinely weak position. Both halves belong in the same conversation, in that order.

1. The Only Lawful Buyer Already Holds a License

Federal law limits who may take ownership of your product, and the limit does not carve out a creditor. Under 21 U.S.C. §360eee-1(c)(3), the trading partners of a wholesale distributor may be only authorized trading partners, and §360eee(23) defines a trading partner as a manufacturer, repackager, wholesale distributor, dispenser, or third-party logistics provider on either end of a transfer of ownership or possession. Section 360eee(2) then says what authorized means for each of those categories, and for a wholesale distributor it means holding a valid license under State law and complying with the reporting duties in §353(e). A finance company is none of the five categories, which means your business cannot lawfully hand it the product even if the security agreement says the product is its collateral.

Run the same rule from the other direction and it gets worse for the creditor. Section 353(e)(4) defines wholesale distribution to include not just the distribution of a prescription drug to a person other than a consumer or patient but the receipt of that drug by a person other than the consumer or patient. Section 353(e)(1)(A) then says no person may engage in wholesale distribution in any State without a license from the State the drug is distributed from. The list of things that are not wholesale distribution runs from intracompany transfers through common carriers who never take ownership, and a foreclosure sale is not on it. The party at the loading dock with a writ is receiving, and receiving is the regulated act.

This is the part an internal recovery model almost never carries, because the model was built on industries where collateral moves freely. A receivables desk that has funded restaurants and staffing firms builds its worst case around repossessing something and selling it, because in every other industry the repossessed thing has a buyer with cash and no paperwork. Here the pool of lawful buyers is a published list that anyone can pull up before making an offer. Section 353(e)(2)(B) required FDA to build a public database of authorized wholesale distributors, so the universe of people who can lawfully take the pallet is not merely small, it is enumerated, and every one of them knows the seller is distressed before the first call ends.

The boundary on all of this is narrow and worth stating precisely. Nothing here stops the security interest from attaching or from being perfected, nothing stops a judgment, nothing shields a personal guarantor, and nothing slows a creditor down by a single day on the receivables side, where a notification and a bank levy work in Indianapolis exactly the way they work in any other industry. What the licensing regime does is collapse the realizable value of one collateral category, which changes what the file is worth rather than whether the debt exists. A distributor who blurs those two things walks into a settlement conversation sounding like somebody who believes the obligation evaporated, and a receivables desk that hears that stops listening to the part of the argument that was actually correct.

2. Passing Title Without a License Is a Felony Here

Indiana attaches a criminal consequence to the same conduct, and it does so in plain words. Ind. Code §25-26-14-11 defines wholesale distribution as distributing legend drugs to persons other than a consumer or patient, with a list of carve outs covering intracompany transfers, hospital group purchasing acquisitions, charitable transfers, emergency sales, dispensing, and samples, none of which reaches a creditor selling seized stock. Ind. Code §25-26-14-26(a) then provides that a person who knowingly or intentionally engages in the wholesale distribution of a legend drug without a license issued under that chapter commits a Level 6 felony. The subject of that sentence is a person, not a distributor, and a liquidation agent reads it the same way you do.

The administrative track runs beside the criminal one and moves considerably faster, because it needs no prosecutor. Ind. Code §25-26-14-21.5 sets out the prohibited acts, among them purchasing legend drugs from an unlicensed distributor and wholesale distribution of drugs that were purchased by a hospital or donated. Subsection (b) then lets the Board of Pharmacy revoke the distributor’s license and assess a civil penalty of up to $10,000 per violation, after a hearing under Ind. Code §4-21.5-3. Per violation is the phrase that matters in a warehouse, because a warehouse holds line items rather than a single act, and nobody in this posture wants a regulator counting.

Federal exposure sits on top of that rather than instead of it. 21 U.S.C. §331(t) makes it a prohibited act to distribute drugs in violation of §353(e), and to fail to comply with the requirements of §360eee-1. Section 333(b)(1)(D) then provides that a person who knowingly distributes drugs in violation of §353(e)(1) shall be imprisoned for not more than 10 years or fined not more than $250,000, or both. Those are the numbers a workout officer’s own compliance department will find in about ten minutes once somebody upstairs asks whether the bank can just sell the inventory.

The practical result is that the people a funder would hire to convert collateral into cash decline the engagement. Auctioneers, asset recovery outfits, and liquidators are not licensed wholesale drug distributors in Indiana and cannot become licensed on a workout timeline, and the ones who understand the chapter will not touch legend drugs at any fee. Nobody bids. That is why the enforcement path in these files runs through receivables, deposit accounts, guaranties, and judgment collection rather than through the building, and it is why the argument that actually moves a settlement number is about which collateral is real, not about whether you owe the money.

3. The Paperwork Is Most of What a Pallet Is Worth

Product without its documentation is not saleable product, and the statute is specific about what documentation means. 21 U.S.C. §360eee(26) defines transaction information as ten data elements including the established name, strength and dosage form, the National Drug Code, container size and count, lot number, transaction date, shipment date, and the business name and address on both ends of the ownership transfer. Section 360eee(27) defines the transaction statement as the seller’s written assertion that it is authorized and that it received the product from an authorized party. The same statement covers receipt of the prior owner’s information and statement, and asserts that the seller did not knowingly ship suspect or illegitimate product or knowingly alter the history. Section 360eee-1(c)(1)(A)(i) then bars a wholesale distributor from accepting ownership at all unless the previous owner supplies those documents.

Since November 27, 2023 the exchange has had to be electronic and interoperable at the package level under §360eee-1(g)(1), and the transaction information has had to carry the product identifier for each package. FDA softened the landing with exemptions for trading partners still fighting their data connections. Those exemptions expired on May 27, 2025 for manufacturers and repackagers, on August 27, 2025 for wholesale distributors, and on November 27, 2025 for dispensers with 26 or more full-time employees. Small dispensers remain exempt from certain requirements until November 27, 2026. As of August 2026 a wholesale distributor in Indianapolis is inside the full regime with no general extension left to point at.

From the creditor’s side this converts a warehouse into a data problem it cannot solve. A secured party that seizes product does not hold the upstream transaction history, cannot truthfully make the §360eee(27) statement about its own receipt, and cannot verify a returned package’s identifier the way §360eee-1(c)(4)(D) requires before further distribution. Product whose chain of custody is interrupted is exactly what §360eee(21) calls suspect product, and the response to suspect product under §360eee-1(c)(4)(A) is quarantine and investigation rather than sale. The creditor has not acquired inventory. It has acquired a quarantine obligation, a storage bill, and a temperature log somebody has to keep signing.

Turn that around and it tells you what to preserve while you are still operating. Section 360eee-1(c)(1)(A)(v) requires you to keep transaction information, history, and statements for not less than 6 years, and §360eee-1(c)(1)(C) requires you to produce them on a request from FDA or a State official in not later than 1 business day and not to exceed 48 hours. A distributor whose systems can do that on demand is a going concern worth more alive than dead, and that difference is the entire reason a rational funder takes a negotiated number instead of a remedy.

4. Article 9 Hands the Question to a Different Statute

Indiana’s Article 9 concedes the point in its own text. Ind. Code §26-1-9.1-401(a) provides that, except as otherwise provided in subsection (b) and in the sections on account debtors, leases, general intangibles, and government collateral, whether a debtor’s rights in collateral may be voluntarily or involuntarily transferred is governed by law other than Article 9. Subsection (b) then kills only private contract restrictions, saying an agreement between the debtor and secured party that prohibits a transfer or makes it a default does not prevent the transfer from taking effect. Read together, the section tells a secured party that its own paper cannot manufacture transferability where a licensing statute has withheld it.

Layer the disposition rules on top of that, because they are what a workout lawyer will actually be reading. Ind. Code §26-1-9.1-610(a) lets a secured party sell, lease, license, or otherwise dispose of collateral after default, and subsection (b) requires that every aspect of the disposition, including the method, manner, time, place, and other terms, be commercially reasonable. Ind. Code §26-1-9.1-627(b)(3) supplies the safe harbor most workout lawyers actually use, which is that a disposition is commercially reasonable if it is made in conformity with reasonable commercial practices among dealers in the type of property that was the subject of the disposition. For prescription drugs, dealers in the type of property are licensed wholesale distributors, and reasonable commercial practice among them is documented and authorized.

Section 627 cuts in both directions, so read the whole of it before building anything on it. Subsection (a) provides that the mere fact a greater amount could have been obtained at a different time or by a different method does not by itself keep the secured party from establishing commercial reasonableness, so a low price is not an automatic defense. The argument that carries weight is narrower and better. A disposition conducted outside the licensed channel is not conformity with practice among dealers in this property, it is conduct the chapter criminalizes, and a secured party that runs one has a serious problem under §§26-1-9.1-625 and 26-1-9.1-626 when the deficiency gets litigated.

We could not locate an Indiana appellate decision applying §26-1-9.1-401(a) to pharmaceutical inventory, and we are not going to imply that one exists. The absence cuts both ways in a negotiation, because nobody can hand a funder a reported case saying it loses and nobody can hand you one saying you win, which leaves both sides reading the same statutory words with the same amount of certainty. That is a more comfortable place to negotiate from than most owners assume, since the party that has to act first is the one contemplating a remedy with criminal exposure attached to getting it wrong. It is also a reason to keep the argument in a letter from counsel rather than in a phone call, because a written analysis of §353(e)(4) and Ind. Code §25-26-14-26 lands on a credit committee, and a phone call lands on whoever answered.

5. The DEA Registration Does Not Travel With the Company

If any part of your line carries controlled substances, a second federal agency has a vote on every structural move you are considering. 21 U.S.C. §823(f) directs the Attorney General to register a distributor of schedule III, IV, or V substances unless registration would be inconsistent with the public interest. The factors it weighs are effective controls against diversion, compliance with State and local law, the applicant’s prior conviction record, and past distribution experience, with the parallel schedule I and II standard at §823(b). Since October 24, 2018, 21 U.S.C. §832(a) has also required every registrant to design and operate a system to identify suspicious orders and to notify DEA on discovering one. None of that pauses because the company is short of cash, and a lapse in it during a workout is the kind of finding that outlives the debt.

The transfer rules are where otherwise sensible restructuring plans die, usually about two weeks after somebody has already told a buyer the deal is clean. 21 C.F.R. §1301.52(b) provides that no registration or any authority conferred by it shall be assigned or otherwise transferred except upon conditions DEA specifically designates and then only pursuant to written consent. Subsection (a) terminates a registration automatically, with no agency action at all, when the registrant ceases legal existence or discontinues business. Subsection (d) requires a registrant transferring the business to notify the Special Agent in Charge at least 14 days in advance with the transferee’s name, address, registration number, and the transfer date, and subsection (e) lets the transfer proceed only if the Special Agent in Charge has not said before that date that it may not occur.

Then read 21 U.S.C. §824(g), which is the provision nobody expects. Where a registrant’s registration has expired or the registrant has ceased to do business in the manner its registration contemplated, DEA may seize or place under seal the controlled substances the registrant owns or possesses, and may not dispose of them until 180 days from the seal. The substances are held for the benefit of the registrant or a successor in interest, so this is custody rather than forfeiture, but a secured creditor watching its collateral sit under federal seal for six months is watching dating and cold chain integrity evaporate on somebody else’s calendar. Section 824(f) goes further where a registration is actually suspended or revoked, sealing the stock and vesting title in the United States once a revocation order is final.

There is a cascade at the end of this that owners consistently miss. Under 21 U.S.C. §824(a)(3), DEA may suspend or revoke a registration on a finding that the registrant’s State license has been suspended, revoked, or denied so that the registrant is no longer authorized by State law to distribute. Lose the Indiana wholesale license because a bond lapsed or an accreditation expired during a cash crisis, and the federal registration is exposed on that ground alone. The §824(c) show cause order arrives no less than 30 days before the appearance date, and a corrective action plan is the only real lever you hold inside that window. Nothing about how the debits are paid should be changed without counsel looking at this sequence first.

6. Your Receivable Shrinks After You Assign It

The other half of a distributor’s collateral is an invoice to a pharmacy chain, a hospital system, or a group purchasing organization, and that invoice is not a fixed number. Contract pricing, chargebacks, rebates, and administrative fees reduce it after the sale, which is why the receivables ledger in this industry never ties to cash the way it does in trucking. Chargebacks are not a private convention either: 42 C.F.R. §447.504 expressly accounts for chargebacks that can be identified with adequate documentation in the treatment of average manufacturer price, which is regulatory recognition that the number invoiced and the number ultimately kept are different numbers.

Indiana’s Article 9 decides who eats the difference, and the answer is the assignee. Ind. Code §26-1-9.1-404(a) provides that unless the account debtor has made an enforceable agreement not to assert defenses, the rights of an assignee are subject to all terms of the agreement between the account debtor and the assignor and to any defense or claim in recoupment arising from the transaction that gave rise to the contract. Clause (a)(2) adds any other defense or claim that accrues before the account debtor receives notification of the assignment. Recoupment arising from the same transaction is in the first clause, which means it is not cut off by a notice, and a contractual chargeback is about as pure an example of that as commercial law produces.

Two provisions in the same section keep this from being a cure-all. Subsection (b) says the account debtor’s claim can be asserted against the assignee only to reduce what the account debtor owes, so your hospital customer cannot turn a rebate dispute into an affirmative recovery from the funder, and subsection (e) removes health care insurance receivables from the section entirely. And §26-1-9.1-406(d) makes a contract term ineffective to the extent it prohibits or restricts assignment of an account or the creation of a security interest in it, so the no-assignment clause in your GPO agreement is not going to keep a UCC-1 off your receivables. The clause you signed does not block the lien; it just travels with the money.

For a funder pricing this, the two facts compound in an uncomfortable direction. A notification under §26-1-9.1-406(a) redirects payment, but it does not convert a chargeback-laden gross receivable into cash at face, and an aging that shows $4,000,000 of gross invoices against contract terms with a large national account is not a $4,000,000 asset to anybody. The reason a receivables desk still starts here is that a discounted account is worth vastly more than an unlicensed pallet, and that comparison, run out loud with your aging on the table, is what a real settlement conversation sounds like. Our page on how a UCC lien intercepts receivables walks through the notification mechanics.

7. The Bond and the Accreditation Are Two Creditors You Forgot

Indiana conditions your license on money and on a private accreditation, and both bite hardest in exactly the quarter you cannot pay them. Ind. Code §25-26-14-15 requires a wholesale drug distributor to post a surety bond of at least $100,000, or an equivalent security acceptable to the Board such as insurance, an irrevocable letter of credit, or funds in a trust account. The bond secures administrative penalties and the Board’s fees and costs, and a separate bond is not required for each additional location. The Board may claim against that security within one year after the license is no longer valid, or sixty days after the conclusion of a proceeding that produces penalties, fees, or costs. A surety that pays a Board claim becomes your creditor by subrogation, and it is a creditor with an indemnity agreement and your personal signature on it.

The accreditation requirement is the sharper edge of the two, because it is not administered by anyone you can appeal to as a citizen. Ind. Code §25-26-14-14 requires a wholesale distributor of legend drugs to obtain and maintain accreditation from the National Association of Boards of Pharmacy’s Verified Accredited Wholesale Distributor program or another accreditation body approved by the Board. The same section requires a Board license and a separate license for each facility or location where wholesale distribution operations are conducted, with a provisional license available to an Indiana applicant actively pursuing accreditation. Your right to sell a legend drug in this state is therefore conditioned on a decision made by a private nonprofit rather than by a state agency.

The case worth reading before you rely on that distinction runs against distributors. In Matrix Distributors, Inc. v. National Association of Boards of Pharmacy, 34 F.4th 190 (3d Cir. 2022), two small secondary wholesalers whose accreditation applications were canceled with little explanation lost dozens of customers and sued NABP and OptumRx under 42 U.S.C. §1983. The Third Circuit held they had not plausibly alleged state action, noting that a state’s use of a private accreditor’s decisions to inform its licensing does not shift the state’s responsibility onto the accreditor. The court did revive a New Jersey common law due process claim against NABP, so the door is not fully shut, but the constitutional route is. Treat accreditation as a commercial relationship you must not let lapse rather than as a right you can litigate quickly.

One thing the federal government has not done is worth stating with a date on it. 21 U.S.C. §360eee-2 directed FDA to set national licensing standards, including bond standards of $100,000 or $25,000 where prior year gross receipts are $10,000,000 or less, and a waiver of a second state’s bond where one is already posted. FDA proposed that rule at 87 FR 6708 on February 4, 2022 and, as of August 2026, has not finalized it, so §360eee-1(a)(6) still controls and licensed means licensed under State law. In Indiana that means the $100,000 floor applies whatever your revenue is, and the federal small-distributor tier is not available to you.

8. Selling the Company Is Exempt, Selling the Pallets Is Not

There is one door in the DSCSA that a restructuring can walk through, and almost nobody writes about it. 21 U.S.C. §360eee(24)(B)(ix) excludes from the definition of transaction the distribution of a product pursuant to the sale or merger of a pharmacy or pharmacies or of a wholesale distributor or wholesale distributors, on the condition that any records required to be maintained for the product are transferred to the new owner. Selling the entity, or merging it, moves the whole inventory without generating a chain of individually documented transactions. Selling the same product off the racks pallet by pallet generates a transaction for every one of them, each demanding an authorized counterparty and a compliant statement.

That single clause is why a going concern sale is worth multiples of a liquidation in this industry, and why a funder with a real understanding of the file would rather have you sold than seized. The buyer in a clause (ix) transaction is an existing licensed distributor acquiring a book of customers, a facility, and stock it can actually move, and the purchase price funds a payoff or a negotiated settlement across the whole creditor stack. The buyer at a foreclosure sale, if one could be found at all, is bidding on product it must re-document before it can resell a single package of it, in a category where §360eee-1(c)(4)(A) makes the alternative to good documentation a quarantine and an investigation conducted in coordination with trading partners who have no reason to help.

The regulatory conditions on that sale are real and they are not fast. Ind. Code §25-26-14-14 requires a license for each facility and accreditation to hold it. The Board of Pharmacy’s own facility licensing guidance treats a change of ownership as a fresh application that produces a new license number, with a new controlled substance registration application required on top of it. Federal law adds the 14 day notice and the DEA stop right at 21 C.F.R. §1301.52(d) and (e). Then there is 21 U.S.C. §360eee-2(d), which directs that the national standards prohibit licensure for a person convicted of a felony relating to wholesale distribution, or who has engaged in a pattern of violations presenting a threat of serious harm. Keeping the compliance record clean while the company is bleeding is not housekeeping, it is preserving the buyer.

The risk in this corner of the analysis deserves stating plainly, because it is where owners in trouble reliably make things worse. Moving inventory, customers, or the license into a new entity you also own, in order to leave the debt behind in the old one, is the classic fact pattern a creditor pleads as a voidable transfer, and Indiana has a chapter for that which the funder’s counsel will find. A sale to a genuine third party for reasonably equivalent value, disclosed and documented, is a different transaction from a shuffle among affiliates, and which one you have done is a question for a lawyer before the first document is signed, not after.

Not Every Box in the Building Carries the Same Rules

Most Indianapolis distributors are mixed businesses, and the regulatory weight varies enormously across the racks. Medical devices are the loose end of the operation. 21 C.F.R. §807.20 imposes FDA establishment registration on manufacturers, specification developers, repackagers, relabelers, reprocessors, and initial importers. Section 807.65(e) and (i) then exempt pharmacies, surgical supply outlets, and similar retail establishments making final delivery, along with persons who dispense devices to the ultimate consumer. A domestic distributor that only buys finished, labeled devices and resells them is generally outside the registration net, which means device inventory is the one category in your building a creditor could plausibly sell to an ordinary buyer.

Durable medical equipment is regulated on the payment side instead. 42 C.F.R. §424.57(d) requires a DMEPOS supplier enrolling, changing ownership, revalidating, or reenrolling to furnish a $50,000 base surety bond from an authorized surety, with an elevated amount where a CMS contractor requires it. The rule specifically provides that a supplier becoming enrolled through a purchase or transfer of assets or ownership interest must post that bond effective from the date of the purchase or transfer in order to bill from that date. Section 424.57(c)(10) separately requires comprehensive liability insurance of at least $300,000. Indiana adds its own layer through Ind. Code §25-26-21, which requires a Board of Pharmacy license for a home medical equipment services provider and a separate license for each Indiana location.

Sorting the building into those buckets before any negotiation is worth more than an hour of argument. Legend drugs are the category a creditor cannot realistically monetize, controlled substances are the category a federal agency can seal, devices and general supplies are the category that behaves like ordinary inventory, and DMEPOS is a payment enrollment with a bond attached rather than a stock of goods at all. A funder that has been shown that breakdown in writing is negotiating against a number it can verify, and in the files we work that is the difference between a conversation and a stalemate.

One caution before anybody builds a plan around the device line. The fact that a creditor could sell your general supply inventory does not mean selling it is good for you, since that stock is often what keeps the accounts current with the customers whose invoices are funding the settlement. Distributors under pressure routinely liquidate the easiest category first because it is the easiest, and then discover that the remaining book of business no longer supports the payment schedule they just agreed to. Decide what gets sold by what it earns rather than by how quickly a buyer can be found, and put that reasoning in writing where a funder can see it, because a plan that visibly protects the revenue is a plan a creditor has a reason to accept.

Where 340B and the Returns Pile Actually Sit

340B comes up in every specialty distribution conversation and it is usually pointed at the wrong party. The duties in 42 U.S.C. §256b(a)(5) run to covered entities and to manufacturers. Subparagraph (A) bars a covered entity from seeking Medicaid payment for a drug already subject to a rebate under section 1927, and subparagraph (B) provides that a covered entity shall not resell or otherwise transfer a covered outpatient drug to a person who is not a patient of the entity. Subparagraph (C) allows the Secretary and the manufacturer to audit, and subparagraph (D) makes a violating covered entity liable to the manufacturer for the amount of the discount. A wholesale distributor is not a covered entity, so your 340B exposure is contractual rather than statutory.

Contractual exposure is not the same thing as small exposure, and in specialty distribution it is frequently the larger of the two. Distribution agreements, GPO participation agreements, and 340B administrator contracts routinely carry indemnities, audit rights, and clawbacks tied to diversion and duplicate discounts, and those obligations do not disappear because the company is in distress. They also do not appear on your aging, which is exactly why they surprise people mid-negotiation. Pull the indemnity and audit clauses out of the three largest supply agreements before you commit to any payment schedule, because a contingent clawback that lands in month four of a settlement plan is how an otherwise workable plan fails.

Returns carry their own arithmetic and it runs the wrong direction for anyone hoping to find value in the back of the building. 21 U.S.C. §360eee-1(c)(1)(B)(i)(II) permits a wholesale distributor to accept a saleable return only if it can associate the product with the transaction information and statement for that product, and §360eee-1(c)(4)(D) requires verification of the product identifier on each sealed homogeneous case, or each package, before further distribution. Nonsaleable product may go back to the manufacturer, the repackager, the selling distributor, or a returns processor under (c)(1)(B)(ii) without the usual documentation, and §360eee(18) defines that reverse logistics role. What that means in a workout is that the returns pile is a cost center with a compliance clock, not a hidden asset, and treating it as recoverable value in a settlement projection is a mistake a funder will happily let you make.

Controlled substance returns run on their own track and cost real money to clear. Disposal runs through the framework in 21 C.F.R. part 1317 rather than through an ordinary waste contractor. A registrant discontinuing business without transferring it must return the certificate of registration and any unexecuted order forms to DEA under 21 C.F.R. §1301.52(c), which then points any controlled substances still in its possession to disposal under part 1317. Budget that line before you commit to a monthly settlement payment, because a compliance obligation that arrives in month three of a plan does not care that the plan was already tight, and a missed disposal is the kind of finding that costs a registration rather than a fee.

Working the File in the Order That Preserves the License

Sequence matters more here than in any other distribution vertical, because the assets that make this company worth buying are permissions rather than things. The Indiana license, the accreditation, the DEA registration, and the trading partner relationships are what a purchaser is paying for, and every one of them can be lost through inattention during a cash crisis in a way that cannot be reversed on a settlement timeline. That is why the first move in these files is a written inventory of every expiring permission with its renewal date, not a call to the funder.

The second move is documentary, and it is the one that changes prices. Assemble the funding agreements with their signature pages, and a current Indiana UCC search showing every financing statement with its filing date. Add the receivables aging split between gross invoiced and contract net, the current bond and accreditation certificates, the DEA registration with its expiration, and a written breakdown of inventory by regulatory category. A funder settles when the alternative to settling looks expensive or slow, and in this industry every fact that makes it look that way is on paper you already have.

Only then does it make sense to decide who is actually going to run the negotiation on your side of the table. Delancey Street is a settlement company rather than a law firm, and attorneys in the Delancey Street network handle the filings, the Board of Pharmacy exposure, and the transfer questions that sit beside a distribution restructuring. The other two companies on this page cover broader consumer and business debt categories and are worth a call if your file is simpler than this one. If you want to compare local options first, our rundown of business debt settlement companies in Indianapolis and our page on how Indianapolis MCA defense files get worked both exist for that purpose.

There is no promised outcome at the end of any of this, and anyone who offers you one on a file with a licensing component attached is selling rather than advising. What a distribution file realistically produces is a range, driven by how many positions there are, how old the advances are, whether any of them rest on paper Indiana treats badly, and whether the company still holds every permission a buyer would need. The single largest variable is time, because the permissions expire on the calendar rather than on your cash flow, and a company that lets a bond lapse or an accreditation run out while it argues about a daily debit has spent the only asset that made the argument worth having.

Who Should You Call? Our Top-Rated Business Debt Firms

One firm on this list works the entire lifecycle of a business debt file, from stopping the daily debits through attorney-led negotiation, UCC lien removal, and a signed release. The other two cover broader debt categories that often sit alongside the advances. Choose accordingly.